Professor Paul Kind
Paul is Professor of Health Outcome Measurement in the Academic Unit of Health Economics within the Leeds Institute of Health Sciences. He has more than 3 decades of accumulated experience in the development and application of methods designed to measure health status in both clinical and economic evaluation.
Prior to his appointment at Leeds he had latterly held a Chair at the Centre for Health, University of York. He is a founder member and past-President of the EuroQoL Group, a multinational research cooperative responsible for the development of EQ-5D and recently stood down from its Scientific Executive after more than 20 years as part of its leadership team.
Until 2013 he was Course Director of the Health Outcomes course at the Vienna School of Clinical Research. Paul has held a number of positions outside the UK - as a Visiting Scientist in the Department of Epidemiology, McGill University, Montreal and a Visiting Professor in the Department of Population Health, at the University of Wisconsin, Madison and in the Department of Pharmacy, University of Uppsala. Sweden. He has served as an elected Board Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) as well as acting as convenor of its Quality of Life Special Interest Group. He has also been an elected Board Member of the International Society for Quality of Life Research (ISOQOL).
Paul provides expert opinion on all aspects of the measurement of health outcomes for a range of public and private sector organisations in the UK and internationally. His current research and teaching activities involve collaboration with colleagues in several Latin American countries, China and Russia where he acted as Lead International Scientist at HSE-University, St Petersburg until the end of 2017..tbcQualifications
Current and previous roles
Professor of Health Outcome Measurement in the Academic Unit of Health Economics within the Leeds Institute of Health Sciences.
Lead International Scientist, Centre for Health Economics, Management and Policy, HSE University, St Petersburg \n Honorary Advisor, World Association of Chinese Quality of Life
Chair in Health Economics at the Centre for Health, University of York
Current research interests
Measuring health outcomes
Current and recent research
Health economists generally favour using the values of the general population when analysing cost-effectiveness - a position shared in the UK by NICE but increasingly coming under scrutiny. Two current studies involving Leeds researchers involve examining ways of taking account of patients' assessment of the "value" of outcomes resulting from their treatment. The Life After Prostate Cancer Diagnosis (LAPCD) study allows men with prostate cancer to record self-reported health status. In a separate study to develop a measure of quality of life in carers of dementia sufferers (DECIDE) the values of carers are being explicitly sought.
EQ-5D is a standardised measure of health-related quality of life (health status) and forms part of the evidence base that is required by many health regulatory agencies around the world. Originally developed for use with adults, a "child-friendly" version was first developed some 15 years ago. That original work led ultimately to EQ-5D-Y, a version of the original 3-level EQ-5D. Collaboration with EuroQoL Group colleagues in Germany, Spain and Sweden to develop a 5-level version of EQ-5D-Y is nearing completion.
Last year a city-wide survey of young people aged 10-15 was completed with more than 6,000 respondents who completed EQ-5D-Y to provide the first population reference "norms" for the UK.
Multiple valuation studies of the EQ-5D-3L health state classification are currently in play - notably in Chile, Colombia and Ecuador. Results from studies in Trinidad and Tobago have been published.
The use of EQ-5D in health and lifestyle surveys is the subject of ongoing work involving UK colleagues in Local Government as well as with Gallup International and a cross-country analysis of 17 Latin American countries.
Paul is currently a member of the Scientific Executive of the EuroQoL Group.
Previous roles:A founding member and President of the EuroQoL Group.
Visiting Professor in the Department of Population Health, at the University of Wisconsin, Madison and in the Department of Pharmacy, University of Uppsala, Sweden.
Elected Board Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Elected Board Member of the International Society for Quality of Life Research (ISOQOL).
- ISPOR (International Society for Pharmaceconomics and Outcomes Research)
- EuroQoL Group
Research groups and institutes
- Leeds Institute of Health Sciences